Interatrial Shunt Devices.

Elevated left atrial pressure during exercise is a hallmark of heart failure (HF) and is associated with adverse left atrial remodeling and poor outcomes. To decompress the pressure-overloaded left atrium in patients with HF, several device-based approaches have been developed to create a permanent, pressure-dependent, left-to-right interatrial shunt. Such approaches are currently in various stages of investigations in both HF with reduced ejection fraction (EF) and HF with preserved EF.

Anticoagulation Bridging in Patients With Left Ventricular Assist Device: A Regional Analysis of HeartMate 3 Recipients.

Advances in left ventricular assist device technologies have led to an improvement in pump hemocompatibility and outcomes. Because of concerns of thromboembolic complications in prior generations of left ventricular assist devices, bridging with parenteral anticoagulants was routinely. Management strategies of subtherapeutic INRs and their effects on the current generation of devices deserve review.

LVAD therapy as a catalyst to heart failure remission and myocardial recovery.

The management of chronic heart failure over the past decade has witnessed tremendous strides in medical optimization and device therapy including the use of left ventricular assist devices (LVAD). What we once thought of as irreversible damage to the myocardium is now demonstrating signs of reverse remodeling and recovery. Myocardial recovery on the structural, molecular, and hemodynamic level is necessary for sufficient recovery to withstand explant and achieve sustained recovery post-LVAD.

Two-Year Follow Up of the LATERAL Clinical Trial: A Focus on Adverse Events.

Background: The LATERAL trial validated the safety and efficacy of the thoracotomy approach for implantation of the HeartWare HVAD System, leading to Food and Drug Administration approval. We sought to analyze 24-month adverse event (AE) rates, including a temporal analysis of the risk profile, associated with the thoracotomy approach for the HVAD system.

Methods: AEs from the LATERAL trial were evaluated over 2 years postimplant.

Primary pulmonary rhabdomyosarcoma: a long-term survivor.

This is a clinical report of a young girl who presented with a large left lung mass, which was found to be alveolar rhabdomyosarcoma, a rare clinical entity. This was successfully treated with surgery, radiation, and chemotherapy. To our knowledge, this is the longest survivor with this disease.

Pulmonary carcinosarcoma.

Pulmonary carcinosarcoma is a rare malignancy, comprising less than 0.3% of all malignant neoplasms of the lung. Since the first report of this tumor by Kika in 1908, approximately 100 cases have been described in the literature.

Giant pulmonary cyst simulating tension pneumothorax.

Giant pulmonary cyst is a rare clinico-pathological entity. It was described as a "windy tumor" by John Floyer in 1726. Since that time, there have been numerous reports on this unique manifestation of emphysema by many authors.